TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Avenacy Introduces Bivalirudin for Injection to the U.S. Market

Tuesday, January 30, 2024

Avenacy, a specialized pharmaceutical company focused on providing essential injectable medications, has announced the launch of Bivalirudin for Injection in the United States. This medication is a therapeutic equivalent generic for Angiomax® for Injection (bivalirudin) and has received approval from the U.S. Food and Drug Administration. Bivalirudin for Injection is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including those with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.

Avenacy's injectable product contains 250 mg of bivalirudin as a lyophilized powder in a single-dose vial for reconstitution. In line with Avenacy's commitment to patient safety and streamlined care, Bivalirudin for Injection will feature the company's unique packaging and labeling designed to facilitate accurate medication selection.

Avenacy will commence shipping Bivalirudin for Injection to wholesale partners this week, supported by a global network of development and FDA-approved cGMP-certified contract manufacturing partners.

Angiomax® is a registered trademark of Sandoz, Inc.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit